GEHCHAN NAJI 4

What Happened

• Gehchan Naji, Chief Medical & Development Officer of Kyverna Therapeutics (KYTX), was granted equity on March 13, 2026: 18,000 restricted stock units (RSUs) and 105,000 derivative equity awards. Both grants are reported at $0 (typical for awards) and were disclosed on a Form 4 filed March 17, 2026. These are grants/awards (code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-03-13; Form 4 filed: 2026-03-17 (filed timely).
• Grants reported: 18,000 RSUs @ $0; 105,000 derivative equity awards @ $0.
• Shares owned after transaction: not specified in this filing.
• Footnote F1 (RSUs): 1/4 of RSUs vest on March 13, 2027, then 1/4 on each one-year anniversary thereafter (4-year annual vesting), subject to continued service.
• Footnote F2 (derivative award): 1/4 vests on March 13, 2027, then 1/48th vests each month thereafter (standard 4-year schedule with 1-year cliff), subject to continued service.
• Exhibit 24 (Power of Attorney) is included with the filing.

Context

• These awards are typical retention/compensation grants and do not represent an open-market buy or sale. The derivative award will convert to common shares as it vests (per the vesting schedule); there is no indication of an immediate cashless sale or exercise in this filing. The filing was made within the required two business days after the transaction date.